In the study published in the journal Science, researchers treated the lab-grown 'mini tumours' with a range of drugs.
They then looked to see how this compared to how successful treatment was in those patients.
The approach found a drug that had a chance of shrinking a patient's tumour in almost nine in 10 cases.
Drugs that did not work in patients also had no effect on the mini tumours. This suggests they could help predict when drugs would not work, researchers said.
The results of the study did not change how patients were treated. However, the approach could be used in the future to help choose treatment.
According to Nicola Valeri, who led the study, the technique needed to be tested in large clinical trials, but that it "has the potential to help deliver truly personalised treatment."
Mini tumours, also called organoids, are tiny balls of cancer cells grown in the lab.
Researchers believe that growing the cancer cells in this way can more closely mirror how they behave inside the body.
They grew mini tumours from biopsies taken from 71 patients with advanced bowel, stomach or bile duct cancer that had spread to other parts of the body.
The researchers tested 55 cancer drugs on the mini tumours, allowing them to compare the results to how each patient's cancer responded to the treatment they were given.
The study focused on stomach and bowel cancer, but Valeri said that "the technique could be applied to a wide variety of cancer types".
Organoids have already been grown from a variety of different cancers, including liver, pancreatic and oesophageal.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
